Skip to main content

Advertisement

SpringerLink
Log in

Cardiovascular Effects of the MEK Inhibitor, Trametinib: A Case Report, Literature Review, and Consideration of Mechanism

  • Published:
Cardiovascular Toxicology Aims and scope Submit manuscript

Abstract

The MEK inhibitor trametinib was approved in 2013 for the treatment of unresectable or metastatic melanoma with a BRAF V600E mutation, the most common pathogenic mutation in melanoma. Trametinib blocks activation of ERK1/2, inhibiting cell proliferation in melanoma. ERK1/2 also protects against multiple types of cardiac insult in mouse models. Trametinib improves survival in melanoma patients, but evidence of unanticipated cardiotoxicity is emerging. Here we describe the case of a patient with metastatic melanoma who developed acute systolic heart failure after trametinib treatment and present the results of the literature review prompted by this case. A patient with no cardiac history presented with a 6.5-mm skin lesion and was found to have metastatic BRAF V600E melanoma. Combination treatment with trametinib and the BRAF inhibitor, dabrafenib, was initiated. The patient’s pre-treatment ejection fraction was 55–60%. His EF declined after 13 days and that was 40% 1 month after treatment. Two months after initiating trametinib, he developed dyspnea and fatigue. We conducted a chart review in the electronic medical record. We conducted a PubMed search using trametinib/adverse effects AND (“heart failure” OR “left ventricular dysfunction” OR hypertension OR cardiotoxicity OR mortality). We also queried the FDA Adverse Events Reporting System for reports of cardiomyopathy, ejection fraction decrease, and left ventricular dysfunction associated with trametinib between January 1, 2013, and July 20, 2017. The literature search retrieved 19 articles, including clinical trials and case reports. Early clinical experience with the MEK inhibitor trametinib suggests that its clinical efficacy may be compromised by cardiotoxicity. Further studies in humans and animals are required to determine the extent of this adverse effect, as well as its underlying mechanisms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Lugowska, I., Kosela-Paterczyk, H., Kozak, K., & Rutkowski, P. (2015). Trametinib: A MEK inhibitor for management of metastatic melanoma. OncoTargets and Therapy, 8, 2251–2259.

    PubMed  PubMed Central  Google Scholar 

  2. Zhao, Y., & Adjei, A. A. (2014). The clinical development of MEK inhibitors. Nature Reviews Clinical Oncology, 11, 385–400.

    Article  CAS  PubMed  Google Scholar 

  3. Infante, J. R., Papadopoulos, K. P., Bendell, J. C., Patnaik, A., Burris, H. A., 3rd, Rasco, D., et al. (2013). A phase 1b study of trametinib, an oral mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. European Journal of Cancer, 49, 2077–2085.

    Article  CAS  PubMed  Google Scholar 

  4. Bridgeman, V. L., Wan, E., Foo, S., Nathan, M. R., Welti, J. C., Frentzas, S., et al. (2016). Preclinical evidence that trametinib enhances the response to antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma. Molecular Cancer Therapeutics, 15, 172–183.

    Article  CAS  PubMed  Google Scholar 

  5. Pervere, L. M., Rakshit, S., Schrock, A. B., Miller, V. A., Ali, S. M., Velcheti, V. (2017). Durable response to combination of dabrafenib and trametinib in BRAF V600E-mutated non-small-cell lung cancer. Clinical Lung Cancer, 18(3), e211–e213.

    Article  CAS  PubMed  Google Scholar 

  6. Cho, H., Matsumoto, S., Fujita, Y., Kuroda, A., Menju, T., Sonobe, M., et al. (2017). Trametinib plus 4-methylumbelliferone exhibits antitumor effects by ERK blockade and CD44 downregulation and affects PD-1 and PD-l1 in malignant pleural mesothelioma. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer, 12(3), 477–490.

  7. Roskoski, R., Jr. (2012). MEK1/2 dual-specificity protein kinases: Structure and regulation. Biochemical and Biophysical Research Communications, 417, 5–10.

    Article  CAS  PubMed  Google Scholar 

  8. Gilmartin, A. G., Bleam, M. R., Groy, A., Moss, K. G., Minthorn, E. A., Kulkarni, S. G., et al. (2011). GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 17, 989–1000.

    Article  CAS  Google Scholar 

  9. Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., et al. (2012). Improved survival with MEK inhibition in BRAF-mutated melanoma. The New England Journal of Medicine, 367, 107–114.

    Article  CAS  PubMed  Google Scholar 

  10. Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., et al. (2002). Mutations of the BRAF gene in human cancer. Nature, 417, 949–954.

    Article  CAS  PubMed  Google Scholar 

  11. Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., et al. (2006). BRAF mutation predicts sensitivity to MEK inhibition. Nature, 439, 358–362.

    Article  CAS  PubMed  Google Scholar 

  12. Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., et al. (2015). Improved overall survival in melanoma with combined dabrafenib and trametinib. The New England Journal of Medicine, 372, 30–39.

    Article  PubMed  Google Scholar 

  13. Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., et al. (2015). Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial. Lancet, 386, 444–451.

    Article  CAS  PubMed  Google Scholar 

  14. Modak, S., Asante-Korang, A., Steinherz, L. J., & Grana, N. (2015). Trametinib-induced left ventricular dysfunction in a child with relapsed neuroblastoma. Journal of Pediatric Hematology/oncology, 37, e381–e383.

    Article  PubMed  Google Scholar 

  15. Tseng, D., Mason, X. L., Neilan, T. G., & Sullivan, R. J. (2016). Cardiogenic shock and respiratory failure in a patient with metastatic melanoma receiving trametinib therapy. The Oncologist, 21, 1136–1137.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Falchook, G. S., Lewis, K. D., Infante, J. R., Gordon, M. S., Vogelzang, N. J., DeMarini, D. J., et al. (2012). Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: A phase 1 dose-escalation trial. The Lancet Oncology, 13, 782–789.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Infante, J. R., Somer, B. G., Park, J. O., Li, C. P., Scheulen, M. E., Kasubhai, S. M., et al. (2014). A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. European Journal of Cancer, 50, 2072–2081.

    Article  CAS  PubMed  Google Scholar 

  18. Planchard, D., Besse, B., Groen, H. J., Souquet, P. J., Quoix, E., Baik, C. S., et al. (2016). Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: An open-label, multicentre phase 2 trial. The Lancet Oncology, 17, 984–993.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kim, K. B., Kefford, R., Pavlick, A. C., Infante, J. R., Ribas, A., Sosman, J. A., et al. (2013). Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 31, 482–489.

    Article  CAS  Google Scholar 

  20. Shah, R. R., & Morganroth, J. (2015). Update on cardiovascular safety of tyrosine kinase inhibitors: With a special focus on qt interval, left ventricular dysfunction and overall risk/benefit. Drug Safety, 38, 693–710.

    Article  CAS  PubMed  Google Scholar 

  21. Tolcher, A. W., Bendell, J. C., Papadopoulos, K. P., Burris, H. A., 3rd, Patnaik, A., Jones, S. F., et al. (2015). A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 26, 58–64.

    Article  CAS  Google Scholar 

  22. Shroff, R. T., Yarchoan, M., O’Connor, A., Gallagher, D., Zahurak, M. L., Rosner, G., et al. (2017). The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. British Journal of Cancer, 116(11), 1402–1407.

    Article  CAS  PubMed  Google Scholar 

  23. Tolcher, A. W., Patnaik, A., Papadopoulos, K. P., Rasco, D. W., Becerra, C. R., Allred, A. J., et al. (2015). Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. Cancer Chemotherapy and Pharmacology, 75, 183–189.

    Article  CAS  PubMed  Google Scholar 

  24. Ghatalia, P., Je, Y., Kaymakcalan, M. D., Sonpavde, G., & Choueiri, T. K. (2015). QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. British Journal of Cancer, 112, 296–305.

    Article  CAS  PubMed  Google Scholar 

  25. Patnaik, A., Tolcher, A., Papadopoulos, K. P., Beeram, M., Rasco, D., Werner, T. L., et al. (2016). Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours. Cancer Chemotherapy and Pharmacology, 78, 491–500.

    Article  CAS  PubMed  Google Scholar 

  26. Thakur, A., & Witteles, R. M. (2014). Cancer therapy-induced left ventricular dysfunction: Interventions and prognosis. Journal of Cardiac Failure, 20, 155–158.

    Article  PubMed  Google Scholar 

  27. Hu, L. A., Chen, W., Martin, N. P., Whalen, E. J., Premont, R. T., & Lefkowitz, R. J. (2003). Gipc interacts with the β1-adrenergic receptor and regulates β1-adrenergic receptor-mediated ERK activation. The Journal of Biological Chemistry, 278, 26295–26301.

    Article  CAS  PubMed  Google Scholar 

  28. Sabri, A., Pak, E., Alcott, S. A., Wilson, B. A., & Steinberg, S. F. (2000). Coupling function of endogenous α(1)- and β-adrenergic receptors in mouse cardiomyocytes. Circulation Research, 86, 1047–1053.

    Article  CAS  PubMed  Google Scholar 

  29. Marber, M. S., Rose, B., & Wang, Y. (2011). The p38 mitogen-activated protein kinase pathway—a potential target for intervention in infarction, hypertrophy, and heart failure. Journal of Molecular and Cellular Cardiology, 51, 485–490.

    Article  CAS  PubMed  Google Scholar 

  30. Kerkela, R., & Force, T. (2006). P38 mitogen-activated protein kinase: A future target for heart failure therapy? Journal of the American College of Cardiology, 48, 556–558.

    Article  PubMed  Google Scholar 

  31. Fischer, P., & Hilfiker-Kleiner, D. (2007). Survival pathways in hypertrophy and heart failure: The gp130-STAT3 axis. Basic Research in Cardiology, 102, 279–297.

    Article  CAS  PubMed  Google Scholar 

  32. Rose, B. A., Force, T., & Wang, Y. (2010). Mitogen-activated protein kinase signaling in the heart: Angels versus demons in a heart-breaking tale. Physiological Reviews, 90, 1507–1546.

    Article  CAS  PubMed  Google Scholar 

  33. Aikawa, R., Komuro, I., Yamazaki, T., Zou, Y., Kudoh, S., Tanaka, M., et al. (1997). Oxidative stress activates extracellular signal-regulated kinases through Src and Ras in cultured cardiac myocytes of neonatal rats. The Journal of Clinical Investigation, 100, 1813–1821.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Bueno, O. F., & Molkentin, J. D. (2002). Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circulation Research, 91, 776–781.

    Article  CAS  PubMed  Google Scholar 

  35. Lou, H., Danelisen, I., & Singal, P. K. (2005). Involvement of mitogen-activated protein kinases in adriamycin-induced cardiomyopathy. American Journal of Physiology Heart and Circulatory Physiology, 288, H1925–H1930.

    Article  CAS  PubMed  Google Scholar 

  36. Lips, D. J., Bueno, O. F., Wilkins, B. J., Purcell, N. H., Kaiser, R. A., Lorenz, J. N., et al. (2004). MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation, 109, 1938–1941.

    Article  CAS  PubMed  Google Scholar 

  37. Purcell, N. H., Wilkins, B. J., York, A., Saba-El-Leil, M. K., Meloche, S., Robbins, J., et al. (2007). Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proceedings of the National Academy of Sciences of the United States of America, 104, 14074–14079.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Duran, J. M., Makarewich, C. A., Trappanese, D., Gross, P., Husain, S., Dunn, J., et al. (2014). Sorafenib cardiotoxicity increases mortality after myocardial infarction. Circulation Research, 114, 1700–1712.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Chavez-MacGregor, M., Zhang, N., Buchholz, T. A., Zhang, Y., Niu, J., Elting, L., et al. (2013). Trastuzumab-related cardiotoxicity among older patients with breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 31, 4222–4228.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

Funding was provided by National Institutes of Health, Center for Advancing Translational Sciences (Grant No. UL1TR001111).

Author information

Authors and Affiliations

  1. Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    Mary Banks & Brian C. Jensen

  2. Health Sciences Library, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    Karen Crowell

  3. Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    Amber Proctor

  4. McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    Brian C. Jensen

  5. Division of Cardiology, University of North Carolina at Chapel Hill, 160 Dental Circle, CB 7075, Chapel Hill, NC, 27599-7075, USA

    Brian C. Jensen

Authors
  1. Mary Banks
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karen Crowell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amber Proctor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Brian C. Jensen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brian C. Jensen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Banks, M., Crowell, K., Proctor, A. et al. Cardiovascular Effects of the MEK Inhibitor, Trametinib: A Case Report, Literature Review, and Consideration of Mechanism. Cardiovasc Toxicol 17, 487–493 (2017). https://doi.org/10.1007/s12012-017-9425-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12012-017-9425-z

Keywords

Search

Navigation